Atossa Therapeutics, Inc. (ATOS) Research

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Market snapshot

Symbol
ATOS
Price
$2.01
Day change
+1.26%
Market cap
$17.3M
P/E ratio
-0.46x
52-week range
1.95-19.35
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$10.00

Peer companies

  • Cognition Therapeutics, Inc. (CGTX)
  • Clene Inc. (CLNN)
  • Coya Therapeutics, Inc. (COYA)
  • Greenwich LifeSciences, Inc. (GLSI)
  • Immix Biopharma, Inc. (IMMX)
  • Oncolytics Biotech Inc. (ONCY)
  • Surrozen, Inc. (SRZN)
  • Instil Bio, Inc. (TIL)

Recent insider activity

  • Steinhart Richard I — A-Award (10000 shares) on 2026-05-12
  • Chen Shu-Chih — A-Award (10000 shares) on 2026-05-12
  • Remmel H. Lawrence — A-Award (10000 shares) on 2026-05-12
  • Finn Jonathan — A-Award (10000 shares) on 2026-05-12
  • Galli Stephen J — A-Award (10000 shares) on 2026-05-12

Open Atossa Therapeutics, Inc. (ATOS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.